KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Other Gross PP&E Adjustments (2016 - 2025)

Jazz Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $271.7 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $271.7 million for Q4 2025, up 15.94% from a year ago — trailing twelve months through Dec 2025 was $271.7 million (up 15.94% YoY), and the annual figure for FY2025 was $271.7 million, up 15.94%.
  • Other Gross PP&E Adjustments for Q4 2025 was $271.7 million at Jazz Pharmaceuticals, up from $130.4 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for JAZZ hit a ceiling of $271.7 million in Q4 2025 and a floor of -$221.1 million in Q1 2024.
  • Median Other Gross PP&E Adjustments over the past 5 years was $59.0 million (2021), compared with a mean of $34.2 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 1522.75% in 2021 and later tumbled 190.83% in 2022.
  • Jazz Pharmaceuticals' Other Gross PP&E Adjustments stood at $218.3 million in 2021, then grew by 0.57% to $219.6 million in 2022, then dropped by 13.81% to $189.3 million in 2023, then increased by 23.8% to $234.3 million in 2024, then grew by 15.94% to $271.7 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $271.7 million (Q4 2025), $130.4 million (Q3 2025), and -$52.1 million (Q2 2025) per Business Quant data.